Literature DB >> 1485931

Alzheimer Disease Assessment Scale: a subtest analysis.

R F Zec1, E S Landreth, S K Vicari, J Belman, E Feldman, A Andrise, R Robbs, R Becker, V Kumar.   

Abstract

The Alzheimer Disease Assessment Scale (ADAS) was administered to 61 Alzheimer patients, 52 elderly controls, and 80 controls between age 7 and 54 years. The Alzheimer group was categorized into different severity levels of dementia based on MMSE scores: very mild (> or = 24), mild (> or = 20), moderate (10-19), and severe (0-9). All 11 ADAS Cognitive subtest scores for the mild, moderate, and severe dementia groups were statistically worse than the elderly control group. This was also the case for the very mild group, except for Naming, Commands, Constructional Praxis, and Ideational Praxis. In terms of magnitude of effect, memory and spontaneous language items were the earliest indicators on the ADAS, while praxis, commands, and naming items were only sensitive later in the course of the disorder. The best single indicators of progression throughout the severity continuum of dementia (i.e., from normal to severe) were the Orientation subtest, the ADAS Cognitive score, and the ADAS Total score. The ADAS Noncognitive subtests generally did not show the progression with increasing dementia that was evident on the ADAS Cognitive subtest. Differences in educational level had no statistically significant effects on any of the ADAS subtest scores, and age differences were few and small in magnitude. The differential rate of decline of the various ADAS subtests appears to reflect both the changing pattern of cognitive impairments as a function of severity of DAT and also to some extent the psychometric limitations of some of the subtests.

Entities:  

Mesh:

Year:  1992        PMID: 1485931     DOI: 10.1097/00002093-199206030-00004

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  12 in total

1.  Visuo-constructional functions in patients with mild cognitive impairment, Alzheimer's disease, and Parkinson's disease.

Authors:  Johann Lehrner; Harald Krakhofer; Claus Lamm; Stefan Macher; Doris Moser; Stefanie Klug; Peter Dal-Bianco; Walter Pirker; Eduard Auff; Gisela Pusswald
Journal:  Neuropsychiatr       Date:  2015-04-11

2.  Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping.

Authors:  Mark D Lindner; John B Hogan; Donald B Hodges; Anitra F Orie; Ping Chen; Jason A Corsa; John E Leet; Kevin W Gillman; Gregory M Rose; Kelli M Jones; Valentin K Gribkoff
Journal:  Psychopharmacology (Berl)       Date:  2006-09-27       Impact factor: 4.530

3.  Norms for CERAD constructional praxis recall.

Authors:  Gerda G Fillenbaum; Bruce M Burchett; Frederick W Unverzagt; Daniel F Rexroth; Kathleen Welsh-Bohmer
Journal:  Clin Neuropsychol       Date:  2011-10-13       Impact factor: 3.535

4.  Neuropsychological test performance and cognitive reserve in healthy aging and the Alzheimer's disease spectrum: a theoretically driven factor analysis.

Authors:  Meghan B Mitchell; Lynn W Shaughnessy; Steven D Shirk; Frances M Yang; Alireza Atri
Journal:  J Int Neuropsychol Soc       Date:  2012-10-08       Impact factor: 2.892

5.  A study of medication-taking and unobtrusive, intelligent reminding.

Authors:  Tamara L Hayes; Kofi Cobbinah; Terry Dishongh; Jeffrey A Kaye; Janna Kimel; Michael Labhard; Todd Leen; Jay Lundell; Umut Ozertem; Misha Pavel; Matthai Philipose; Kevin Rhodes; Sengul Vurgun
Journal:  Telemed J E Health       Date:  2009-10       Impact factor: 3.536

6.  Dimensions of physical frailty and cognitive function in older adults with amnestic mild cognitive impairment.

Authors:  E L McGough; B B Cochrane; K C Pike; R G Logsdon; S M McCurry; L Teri
Journal:  Ann Phys Rehabil Med       Date:  2013-03-26

7.  A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan overall dementia assessment.

Authors:  M Brazzelli; E Capitani; S Della Sala; H Spinnler; M Zuffi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-12       Impact factor: 10.154

8.  Cultural adaptation of Alzheimer's disease assessment scale-cognitive subscale for use in India and validation of the Tamil version for South Indian population.

Authors:  Monisha Lakshminarayanan; Sridhar Vaitheswaran; Nivedhitha Srinivasan; Gayathri Nagarajan; Ahalya Ganesh; Kunnukatil S Shaji; Mina Chandra; Murali Krishna; Aimee Spector
Journal:  Aging Ment Health       Date:  2021-01-25       Impact factor: 3.514

9.  Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil.

Authors:  Cecilia M Persson; Asa K Wallin; Sten Levander; Lennart Minthon
Journal:  BMC Neurol       Date:  2009-02-10       Impact factor: 2.474

10.  The Hawthorne Effect: a randomised, controlled trial.

Authors:  Rob McCarney; James Warner; Steve Iliffe; Robbert van Haselen; Mark Griffin; Peter Fisher
Journal:  BMC Med Res Methodol       Date:  2007-07-03       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.